Proven Efficacy and Safety
Hizentra is proven effective in both CIDP and PI
CSL Behring has been a leading innovator in SCIg replacement therapy
Hizentra is the 1st SCIg approved:
- With a 20% formulation in the US
- For up to 2-week dosing*
- For CIDP
Hizentra is indicated for the treatment of primary immune deficiency (PI) in adults and pediatric patients 2 years and older, and for maintenance therapy in adults with chronic inflammatory demyelinating polyneuropathy (CIDP) to prevent relapse of neuromuscular disability and impairment.
Frequently asked questions about Hizentra
Want to know more about Hizentra? See answers to many prescribers' frequently asked questions.
Frequently asked questionsFlexibility with Hizentra self-administration
Create personalized treatment plans to meet your patients' clinical needs and personal preferences.
See why Hizentra may be right for your patients
*Primary immunodeciency.